Tucatinib in Combination with Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer
home / news-network / tucatinib-in-combination-with-trastuzumab-and-capecitabine-in-her2-metastatic-breast-cancer
Sara A. Hurvitz, MD, discusses updated results of the HER2CLIMB trial of tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer.